Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 210 entries
Sorted by: Best Match Show Resources per page
Prospective multicenter registry of hybrid coronary artery revascularization combined with non-saphenous vein graft surgical bypass and percutaneous coronary intervention using everolimus eluting metallic stents (PRIDE-METAL study).

Cardiovascular intervention and therapeutics

Watanabe Y, Fujita T, Doi H, Tobaru T, Takanashi S, Kinoshita Y, Okawa Y, Fuku Y, Komiya T, Tsujita K, Fukui T, Shimokawa T, Kozuma K.
PMID: 34003447
Cardiovasc Interv Ther. 2021 May 18; doi: 10.1007/s12928-021-00784-5. Epub 2021 May 18.

The concept of hybrid coronary revascularization (HCR) combines the advantages of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) to improve the treatment of patients with complex multivessel disease. This study aimed to investigate a 1-year clinical...

Cite
Watanabe Y, Fujita T, Doi H, et al. Prospective multicenter registry of hybrid coronary artery revascularization combined with non-saphenous vein graft surgical bypass and percutaneous coronary intervention using everolimus eluting metallic stents (PRIDE-METAL study). Cardiovasc Interv Ther. 2021;doi: 10.1007/s12928-021-00784-5.
Watanabe, Y., Fujita, T., Doi, H., Tobaru, T., Takanashi, S., Kinoshita, Y., Okawa, Y., Fuku, Y., Komiya, T., Tsujita, K., Fukui, T., Shimokawa, T., & Kozuma, K. (2021). Prospective multicenter registry of hybrid coronary artery revascularization combined with non-saphenous vein graft surgical bypass and percutaneous coronary intervention using everolimus eluting metallic stents (PRIDE-METAL study). Cardiovascular intervention and therapeutics, . https://doi.org/10.1007/s12928-021-00784-5
Watanabe, Yusuke, et al. "Prospective multicenter registry of hybrid coronary artery revascularization combined with non-saphenous vein graft surgical bypass and percutaneous coronary intervention using everolimus eluting metallic stents (PRIDE-METAL study)." Cardiovascular intervention and therapeutics vol. (2021). doi: https://doi.org/10.1007/s12928-021-00784-5
Watanabe Y, Fujita T, Doi H, Tobaru T, Takanashi S, Kinoshita Y, Okawa Y, Fuku Y, Komiya T, Tsujita K, Fukui T, Shimokawa T, Kozuma K. Prospective multicenter registry of hybrid coronary artery revascularization combined with non-saphenous vein graft surgical bypass and percutaneous coronary intervention using everolimus eluting metallic stents (PRIDE-METAL study). Cardiovasc Interv Ther. 2021 May 18; doi: 10.1007/s12928-021-00784-5. Epub 2021 May 18. PMID: 34003447.
Copy Download .nbib Format: NLM
Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.

International journal of hematology

Yamada Y, Ikegawa S, Najima Y, Atsuta Y, Konuma R, Adachi H, Wada A, Kishida Y, Konishi T, Nagata A, Kaito S, Nagata R, Noguchi Y, Marumo A, Mukae J, Inamoto K, Toya T, Igarashi A, Kobayashi T, Sakamaki H, Ohashi K, Doki N.
PMID: 34652634
Int J Hematol. 2021 Oct 15; doi: 10.1007/s12185-021-03233-4. Epub 2021 Oct 15.

Fludarabine with intravenous busulfan (6.4 mg/kg; FB2) and fludarabine with intermediate-dose melphalan (140 mg/m

Cite
Yamada Y, Ikegawa S, Najima Y, et al. Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI. Int J Hematol. 2021;doi: 10.1007/s12185-021-03233-4.
Yamada, Y., Ikegawa, S., Najima, Y., Atsuta, Y., Konuma, R., Adachi, H., Wada, A., Kishida, Y., Konishi, T., Nagata, A., Kaito, S., Nagata, R., Noguchi, Y., Marumo, A., Mukae, J., Inamoto, K., Toya, T., Igarashi, A., Kobayashi, T., Sakamaki, H., Ohashi, K., & Doki, N. (2021). Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI. International journal of hematology, . https://doi.org/10.1007/s12185-021-03233-4
Yamada, Yuta, et al. "Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI." International journal of hematology vol. (2021). doi: https://doi.org/10.1007/s12185-021-03233-4
Yamada Y, Ikegawa S, Najima Y, Atsuta Y, Konuma R, Adachi H, Wada A, Kishida Y, Konishi T, Nagata A, Kaito S, Nagata R, Noguchi Y, Marumo A, Mukae J, Inamoto K, Toya T, Igarashi A, Kobayashi T, Sakamaki H, Ohashi K, Doki N. Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI. Int J Hematol. 2021 Oct 15; doi: 10.1007/s12185-021-03233-4. Epub 2021 Oct 15. PMID: 34652634.
Copy Download .nbib Format: NLM
Relationship between hemodynamic alteration and sympathetic nerve activation following a single oral dose of cinnamtannin A2.

Free radical research

Koizumi R, Fushimi T, Sato Y, Fujii Y, Sato H, Osakabe N.
PMID: 32321314
Free Radic Res. 2021 May;55(5):491-498. doi: 10.1080/10715762.2020.1759805. Epub 2021 Jul 12.

We previously found that a single dose of B-type procyanidin mixture increase in skeletal muscle blood flow (BF). We compared BF changes following administration of (-)-epicatechin (EC, monomer) and the B-type procyanidins procyanidin B2 (B2, dimer), procyanidin C1 (C1,...

Cite
Koizumi R, Fushimi T, Sato Y, et al. Relationship between hemodynamic alteration and sympathetic nerve activation following a single oral dose of cinnamtannin A2. Free Radic Res. 2021;55(5):491-498doi: 10.1080/10715762.2020.1759805.
Koizumi, R., Fushimi, T., Sato, Y., Fujii, Y., Sato, H., & Osakabe, N. (2021). Relationship between hemodynamic alteration and sympathetic nerve activation following a single oral dose of cinnamtannin A2. Free radical research, 55(5), 491-498. https://doi.org/10.1080/10715762.2020.1759805
Koizumi, Ryo, et al. "Relationship between hemodynamic alteration and sympathetic nerve activation following a single oral dose of cinnamtannin A2." Free radical research vol. 55,5 (2021): 491-498. doi: https://doi.org/10.1080/10715762.2020.1759805
Koizumi R, Fushimi T, Sato Y, Fujii Y, Sato H, Osakabe N. Relationship between hemodynamic alteration and sympathetic nerve activation following a single oral dose of cinnamtannin A2. Free Radic Res. 2021 May;55(5):491-498. doi: 10.1080/10715762.2020.1759805. Epub 2021 Jul 12. PMID: 32321314.
Copy Download .nbib Format: NLM
Impact of a learning health system on acute care and medical complications after intracerebral hemorrhage.

Learning health systems

Matsumoto K, Nohara Y, Wakata Y, Yamashita T, Kozuma Y, Sugeta R, Yamakawa M, Yamauchi F, Miyashita E, Takezaki T, Yamashiro S, Nishi T, Machida J, Soejima H, Kamouchi M, Nakashima N.
PMID: 33889732
Learn Health Syst. 2020 Mar 10;5(2):e10223. doi: 10.1002/lrh2.10223. eCollection 2021 Apr.

INTRODUCTION: Patients with stroke often experience pneumonia during the acute stage after stroke onset. Oral care may be effective in reducing the risk of stroke-associated pneumonia (SAP). We aimed to determine the changes in oral care, as well as...

Cite
Matsumoto K, Nohara Y, Wakata Y, et al. Impact of a learning health system on acute care and medical complications after intracerebral hemorrhage. Learn Health Syst. 2020;5(2):e10223doi: 10.1002/lrh2.10223.
Matsumoto, K., Nohara, Y., Wakata, Y., Yamashita, T., Kozuma, Y., Sugeta, R., Yamakawa, M., Yamauchi, F., Miyashita, E., Takezaki, T., Yamashiro, S., Nishi, T., Machida, J., Soejima, H., Kamouchi, M., & Nakashima, N. (2021). Impact of a learning health system on acute care and medical complications after intracerebral hemorrhage. Learning health systems, 5(2), e10223. https://doi.org/10.1002/lrh2.10223
Matsumoto, Koutarou, et al. "Impact of a learning health system on acute care and medical complications after intracerebral hemorrhage." Learning health systems vol. 5,2 (2021): e10223. doi: https://doi.org/10.1002/lrh2.10223
Matsumoto K, Nohara Y, Wakata Y, Yamashita T, Kozuma Y, Sugeta R, Yamakawa M, Yamauchi F, Miyashita E, Takezaki T, Yamashiro S, Nishi T, Machida J, Soejima H, Kamouchi M, Nakashima N. Impact of a learning health system on acute care and medical complications after intracerebral hemorrhage. Learn Health Syst. 2020 Mar 10;5(2):e10223. doi: 10.1002/lrh2.10223. eCollection 2021 Apr. PMID: 33889732; PMCID: PMC8051343.
Copy Download .nbib Format: NLM
Glycated albumin as biomarker: Evidence and its outcomes.

Journal of diabetes and its complications

Kohzuma T, Tao X, Koga M.
PMID: 34507877
J Diabetes Complications. 2021 Nov;35(11):108040. doi: 10.1016/j.jdiacomp.2021.108040. Epub 2021 Aug 30.

Glycemic control markers are important for the diagnosis and treatment of diabetes. Hemoglobin A1c (A1C) is an important marker that is mandatory in routine medical examinations; however, it is well known that it has some limitations. In this review,...

Cite
Kohzuma T, Tao X, Koga M. Glycated albumin as biomarker: Evidence and its outcomes. J Diabetes Complications. 2021;35(11):108040doi: 10.1016/j.jdiacomp.2021.108040.
Kohzuma, T., Tao, X., & Koga, M. (2021). Glycated albumin as biomarker: Evidence and its outcomes. Journal of diabetes and its complications, 35(11), 108040. https://doi.org/10.1016/j.jdiacomp.2021.108040
Kohzuma, Takuji, et al. "Glycated albumin as biomarker: Evidence and its outcomes." Journal of diabetes and its complications vol. 35,11 (2021): 108040. doi: https://doi.org/10.1016/j.jdiacomp.2021.108040
Kohzuma T, Tao X, Koga M. Glycated albumin as biomarker: Evidence and its outcomes. J Diabetes Complications. 2021 Nov;35(11):108040. doi: 10.1016/j.jdiacomp.2021.108040. Epub 2021 Aug 30. PMID: 34507877.
Copy Download .nbib Format: NLM
ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.

Thoracic cancer

Yamamoto K, Toyokawa G, Kozuma Y, Shoji F, Yamazaki K, Takeo S.
PMID: 33939293
Thorac Cancer. 2021 Jun;12(11):1761-1764. doi: 10.1111/1759-7714.13962. Epub 2021 May 03.

The incidence of central nervous system (CNS) metastases in patients with anaplastic lymphoma kinase (ALK) fusion gene-positive (ALK+) non-small cell lung cancer (NSCLC) is high, ranging from approximately 20%-70%. Although ALK inhibitors (ALKis) are generally effective for CNS metastases...

Cite
Yamamoto K, Toyokawa G, Kozuma Y, et al. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report. Thorac Cancer. 2021;12(11):1761-1764doi: 10.1111/1759-7714.13962.
Yamamoto, K., Toyokawa, G., Kozuma, Y., Shoji, F., Yamazaki, K., & Takeo, S. (2021). ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report. Thoracic cancer, 12(11), 1761-1764. https://doi.org/10.1111/1759-7714.13962
Yamamoto, Keisuke, et al. "ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report." Thoracic cancer vol. 12,11 (2021): 1761-1764. doi: https://doi.org/10.1111/1759-7714.13962
Yamamoto K, Toyokawa G, Kozuma Y, Shoji F, Yamazaki K, Takeo S. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report. Thorac Cancer. 2021 Jun;12(11):1761-1764. doi: 10.1111/1759-7714.13962. Epub 2021 May 03. PMID: 33939293; PMCID: PMC8169298.
Copy Download .nbib Format: NLM
Prognostic impact of postprocedure stroke volume in patients with low-gradient aortic stenosis.

Open heart

Nara Y, Kataoka A, Watanabe Y, Makoto N, Hioki H, Kawashima H, Fukuko N, Kozuma K, Shirai S, Tada N, Araki M, Naganuma T, Yamanaka F, Ueno H, Tabata M, Mizutani K, Higashimori A, Takagi K, Yamamoto M, Hayashida K.
PMID: 31218001
Open Heart. 2019 May 24;6(1):e000988. doi: 10.1136/openhrt-2018-000988. eCollection 2019.

OBJECTIVE: The effect of postoperative blood flow status on the prognosis of patients with low-gradient severe aortic stenosis (AS) has not been examined. Severe AS is associated with a higher mortality rate after transcatheter aortic valve implantation (TAVI). We...

Cite
Nara Y, Kataoka A, Watanabe Y, et al. Prognostic impact of postprocedure stroke volume in patients with low-gradient aortic stenosis. Open Heart. 2019;6(1):e000988doi: 10.1136/openhrt-2018-000988.
Nara, Y., Kataoka, A., Watanabe, Y., Makoto, N., Hioki, H., Kawashima, H., Fukuko, N., Kozuma, K., Shirai, S., Tada, N., Araki, M., Naganuma, T., Yamanaka, F., Ueno, H., Tabata, M., Mizutani, K., Higashimori, A., Takagi, K., Yamamoto, M., & Hayashida, K. (2019). Prognostic impact of postprocedure stroke volume in patients with low-gradient aortic stenosis. Open heart, 6(1), e000988. https://doi.org/10.1136/openhrt-2018-000988
Nara, Yugo, et al. "Prognostic impact of postprocedure stroke volume in patients with low-gradient aortic stenosis." Open heart vol. 6,1 (2019): e000988. doi: https://doi.org/10.1136/openhrt-2018-000988
Nara Y, Kataoka A, Watanabe Y, Makoto N, Hioki H, Kawashima H, Fukuko N, Kozuma K, Shirai S, Tada N, Araki M, Naganuma T, Yamanaka F, Ueno H, Tabata M, Mizutani K, Higashimori A, Takagi K, Yamamoto M, Hayashida K. Prognostic impact of postprocedure stroke volume in patients with low-gradient aortic stenosis. Open Heart. 2019 May 24;6(1):e000988. doi: 10.1136/openhrt-2018-000988. eCollection 2019. PMID: 31218001; PMCID: PMC6546191.
Copy Download .nbib Format: NLM
KDIGO recommendations for the evaluation of glycemic control in advanced chronic kidney disease.

Kidney international

Fonseca V, Kohzuma T, Galindo RJ, DeSouza C.
PMID: 34906417
Kidney Int. 2021 Dec 11; doi: 10.1016/j.kint.2021.11.020. Epub 2021 Dec 11.

No abstract available.

Cite
Fonseca V, Kohzuma T, Galindo RJ, et al. KDIGO recommendations for the evaluation of glycemic control in advanced chronic kidney disease. Kidney Int. 2021;doi: 10.1016/j.kint.2021.11.020.
Fonseca, V., Kohzuma, T., Galindo, R. J., & DeSouza, C. (2021). KDIGO recommendations for the evaluation of glycemic control in advanced chronic kidney disease. Kidney international, . https://doi.org/10.1016/j.kint.2021.11.020
Fonseca, Vivian, et al. "KDIGO recommendations for the evaluation of glycemic control in advanced chronic kidney disease." Kidney international vol. (2021). doi: https://doi.org/10.1016/j.kint.2021.11.020
Fonseca V, Kohzuma T, Galindo RJ, DeSouza C. KDIGO recommendations for the evaluation of glycemic control in advanced chronic kidney disease. Kidney Int. 2021 Dec 11; doi: 10.1016/j.kint.2021.11.020. Epub 2021 Dec 11. PMID: 34906417.
Copy Download .nbib Format: NLM
Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm.

Journal of clinical medicine

Sato R, Sakamoto K, Kaikita K, Tsujita K, Nakao K, Ozaki Y, Kimura K, Ako J, Noguchi T, Yasuda S, Suwa S, Fujimoto K, Nakama Y, Morita T, Shimizu W, Saito Y, Hirohata A, Morita Y, Inoue T, Okamura A, Mano T, Hirata K, Tanabe K, Shibata Y, Owa M, Funayama H, Kokubu N, Kozuma K, Uemura S, Toubaru T, Saku K, Ohshima S, Nishimura K, Miyamoto Y, Ogawa H, Ishihara M.
PMID: 32498247
J Clin Med. 2020 Jun 02;9(6). doi: 10.3390/jcm9061686.

While prognoses in relation to myocardial infarction (MI) type have been elucidated in past reports, the results were not consistent, perhaps due to occurrence of Type 2 MI with CVS and its mortality. The Japanese registry of acute Myocardial...

Cite
Sato R, Sakamoto K, Kaikita K, et al. Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm. J Clin Med. 2020;9(6)doi: 10.3390/jcm9061686.
Sato, R., Sakamoto, K., Kaikita, K., Tsujita, K., Nakao, K., Ozaki, Y., Kimura, K., Ako, J., Noguchi, T., Yasuda, S., Suwa, S., Fujimoto, K., Nakama, Y., Morita, T., Shimizu, W., Saito, Y., Hirohata, A., Morita, Y., Inoue, T., Okamura, A., Mano, T., Hirata, K., Tanabe, K., Shibata, Y., Owa, M., Funayama, H., Kokubu, N., Kozuma, K., Uemura, S., Toubaru, T., Saku, K., Ohshima, S., Nishimura, K., Miyamoto, Y., Ogawa, H., & Ishihara, M. (2020). Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm. Journal of clinical medicine, 9(6), . https://doi.org/10.3390/jcm9061686
Sato, Ryota, et al. "Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm." Journal of clinical medicine vol. 9,6 (2020). doi: https://doi.org/10.3390/jcm9061686
Sato R, Sakamoto K, Kaikita K, Tsujita K, Nakao K, Ozaki Y, Kimura K, Ako J, Noguchi T, Yasuda S, Suwa S, Fujimoto K, Nakama Y, Morita T, Shimizu W, Saito Y, Hirohata A, Morita Y, Inoue T, Okamura A, Mano T, Hirata K, Tanabe K, Shibata Y, Owa M, Funayama H, Kokubu N, Kozuma K, Uemura S, Toubaru T, Saku K, Ohshima S, Nishimura K, Miyamoto Y, Ogawa H, Ishihara M. Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm. J Clin Med. 2020 Jun 02;9(6). doi: 10.3390/jcm9061686. PMID: 32498247; PMCID: PMC7356040.
Copy Download .nbib Format: NLM
Multiple system atrophy variant with severe hippocampal pathology.

Brain pathology (Zurich, Switzerland)

Ando T, Riku Y, Akagi A, Miyahara H, Hirano M, Ikeda T, Yabata H, Koizumi R, Oba C, Morozumi S, Yasui K, Goto A, Katayama T, Sakakibara S, Aiba I, Sakai M, Konagaya M, Mori K, Ito Y, Yuasa H, Nomura M, Porto KJL, Mitsui J, Tsuji S, Mimuro M, Hashizume Y, Katsuno M, Iwasaki Y, Yoshida M.
PMID: 34255887
Brain Pathol. 2022 Jan;32(1):e13002. doi: 10.1111/bpa.13002. Epub 2021 Jul 13.

The striatonigral and olivopontocerebellar systems are known to be vulnerable in multiple system atrophy (MSA), showing neuronal loss, astrogliosis, and alpha-synuclein-immunoreactive inclusions. MSA patients who displayed abundant neuronal cytoplasmic inclusions (NCIs) in the regions other than the striatonigral or...

Cite
Ando T, Riku Y, Akagi A, et al. Multiple system atrophy variant with severe hippocampal pathology. Brain Pathol. 2021;32(1):e13002doi: 10.1111/bpa.13002.
Ando, T., Riku, Y., Akagi, A., Miyahara, H., Hirano, M., Ikeda, T., Yabata, H., Koizumi, R., Oba, C., Morozumi, S., Yasui, K., Goto, A., Katayama, T., Sakakibara, S., Aiba, I., Sakai, M., Konagaya, M., Mori, K., Ito, Y., Yuasa, H., Nomura, M., Porto, K. J. L., Mitsui, J., Tsuji, S., Mimuro, M., Hashizume, Y., Katsuno, M., Iwasaki, Y., & Yoshida, M. (2022). Multiple system atrophy variant with severe hippocampal pathology. Brain pathology (Zurich, Switzerland), 32(1), e13002. https://doi.org/10.1111/bpa.13002
Ando, Takashi, et al. "Multiple system atrophy variant with severe hippocampal pathology." Brain pathology (Zurich, Switzerland) vol. 32,1 (2022): e13002. doi: https://doi.org/10.1111/bpa.13002
Ando T, Riku Y, Akagi A, Miyahara H, Hirano M, Ikeda T, Yabata H, Koizumi R, Oba C, Morozumi S, Yasui K, Goto A, Katayama T, Sakakibara S, Aiba I, Sakai M, Konagaya M, Mori K, Ito Y, Yuasa H, Nomura M, Porto KJL, Mitsui J, Tsuji S, Mimuro M, Hashizume Y, Katsuno M, Iwasaki Y, Yoshida M. Multiple system atrophy variant with severe hippocampal pathology. Brain Pathol. 2022 Jan;32(1):e13002. doi: 10.1111/bpa.13002. Epub 2021 Jul 13. PMID: 34255887.
Copy Download .nbib Format: NLM
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.

The Journal of infectious diseases

Hsu YC, Yeh ML, Wong GL, Chen CH, Peng CY, Buti M, Enomoto M, Xie Q, Trinh H, Preda C, Liu L, Cheung KS, Yeo YH, Hoang J, Huang CF, Riveiro-Barciela M, Kozuka R, Istratescu D, Tsai PC, Accarino EV, Lee DH, Wu JL, Huang JF, Dai CY, Cheung R, Chuang WL, Yuen MF, Wong VW, Yu ML, Nguyen MH.
PMID: 33999179
J Infect Dis. 2021 Dec 01;224(11):1890-1899. doi: 10.1093/infdis/jiab241.

BACKGROUND: Long-term incidences and baseline determinants of functional cure (hepatitis B surface antigen [HBsAg] seroclearance) during entecavir (ETV) or tenofovir disoproxil fumarate (TDF) treatment are incompletely understood.METHODS: This is an international multicenter cohort study of treatment-naive patients with chronic...

Cite
Hsu YC, Yeh ML, Wong GL, et al. Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. J Infect Dis. 2021;224(11):1890-1899doi: 10.1093/infdis/jiab241.
Hsu, Y. C., Yeh, M. L., Wong, G. L., Chen, C. H., Peng, C. Y., Buti, M., Enomoto, M., Xie, Q., Trinh, H., Preda, C., Liu, L., Cheung, K. S., Yeo, Y. H., Hoang, J., Huang, C. F., Riveiro-Barciela, M., Kozuka, R., Istratescu, D., Tsai, P. C., Accarino, E. V., Lee, D. H., Wu, J. L., Huang, J. F., Dai, C. Y., Cheung, R., Chuang, W. L., Yuen, M. F., Wong, V. W., Yu, M. L., & Nguyen, M. H. (2021). Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. The Journal of infectious diseases, 224(11), 1890-1899. https://doi.org/10.1093/infdis/jiab241
Hsu, Yao-Chun, et al. "Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B." The Journal of infectious diseases vol. 224,11 (2021): 1890-1899. doi: https://doi.org/10.1093/infdis/jiab241
Hsu YC, Yeh ML, Wong GL, Chen CH, Peng CY, Buti M, Enomoto M, Xie Q, Trinh H, Preda C, Liu L, Cheung KS, Yeo YH, Hoang J, Huang CF, Riveiro-Barciela M, Kozuka R, Istratescu D, Tsai PC, Accarino EV, Lee DH, Wu JL, Huang JF, Dai CY, Cheung R, Chuang WL, Yuen MF, Wong VW, Yu ML, Nguyen MH. Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. J Infect Dis. 2021 Dec 01;224(11):1890-1899. doi: 10.1093/infdis/jiab241. PMID: 33999179.
Copy Download .nbib Format: NLM
Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II)　- Final 2-Year Follow-up Results of a Postmarketing Observational Study.

Circulation journal : official journal of the Japanese Circulation Society

Nakamura M, Kitazono T, Kozuma K, Sekine T, Nakamura S, Shiosakai K, Tanabe A, Iizuka T.
PMID: 33012746
Circ J. 2020 Oct 23;84(11):1981-1989. doi: 10.1253/circj.CJ-20-0253. Epub 2020 Oct 02.

BACKGROUND: PRASFIT-Practice II is a postmarketing observational study conducted in 4,155 Japanese patients with ischemic heart disease (IHD) who received long-term prasugrel. The data were used to assess the utility of Academic Research Consortium for High Bleeding Risk (ARC-HBR)...

Cite
Nakamura M, Kitazono T, Kozuma K, et al. Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II)　- Final 2-Year Follow-up Results of a Postmarketing Observational Study. Circ J. 2020;84(11):1981-1989doi: 10.1253/circj.CJ-20-0253.
Nakamura, M., Kitazono, T., Kozuma, K., Sekine, T., Nakamura, S., Shiosakai, K., Tanabe, A., & Iizuka, T. (2020). Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II)　- Final 2-Year Follow-up Results of a Postmarketing Observational Study. Circulation journal : official journal of the Japanese Circulation Society, 84(11), 1981-1989. https://doi.org/10.1253/circj.CJ-20-0253
Nakamura, Masato, et al. "Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II)　- Final 2-Year Follow-up Results of a Postmarketing Observational Study." Circulation journal : official journal of the Japanese Circulation Society vol. 84,11 (2020): 1981-1989. doi: https://doi.org/10.1253/circj.CJ-20-0253
Nakamura M, Kitazono T, Kozuma K, Sekine T, Nakamura S, Shiosakai K, Tanabe A, Iizuka T. Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II)　- Final 2-Year Follow-up Results of a Postmarketing Observational Study. Circ J. 2020 Oct 23;84(11):1981-1989. doi: 10.1253/circj.CJ-20-0253. Epub 2020 Oct 02. PMID: 33012746.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 210 entries